SRR661133
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.481
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.404
- UV_RESPONSE_DN+0.327
- ESTROGEN_RESPONSE_EARLY+0.311
- KRAS_SIGNALING_DN+0.304
- ESTROGEN_RESPONSE_LATE+0.296
- HYPOXIA+0.270
- PANCREAS_BETA_CELLS+0.257
- KRAS_SIGNALING_UP+0.242
- ALLOGRAFT_REJECTION+0.236
Top 10 suppressed
- MYC_TARGETS_V1-0.410
- DNA_REPAIR-0.397
- MYC_TARGETS_V2-0.353
- E2F_TARGETS-0.352
- WNT_BETA_CATENIN_SIGNALING-0.315
- UNFOLDED_PROTEIN_RESPONSE-0.314
- INTERFERON_ALPHA_RESPONSE-0.308
- G2M_CHECKPOINT-0.292
- MITOTIC_SPINDLE-0.289
- CHOLESTEROL_HOMEOSTASIS-0.267
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615213 | GTEX | — | 0.904 |
| 2 | SRR662007 | GTEX | — | 0.889 |
| 3 | SRR613474 | GTEX | — | 0.888 |
| 4 | SRR656564 | GTEX | — | 0.881 |
| 5 | SRR1319019 | GTEX | — | 0.856 |
| 6 | BS_YB2RXRHT | pilocytic astrocytoma | — | 0.856 |
| 7 | SRR600533 | GTEX | — | 0.855 |
| 8 | BS_B7X8VXQ3 | Ganglioglioma | — | 0.851 |
| 9 | SRR659780 | GTEX | — | 0.849 |
| 10 | SRR5088862 | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.481 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.404 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.327 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.311 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.304 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.296 | Idelalisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.257 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.242 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.236 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.234 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.218 | Idelalisib | — uncovered |
| COAGULATION | 0.217 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.193 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.188 | Inavolisib | — uncovered |
| COMPLEMENT | 0.181 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.145 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.141 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.141 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.127 | Temsirolimus | — uncovered |